Skip to content

Study · Animal study (in vivo) · rat · 2025

5 results

ARA290, an alternative of erythropoietin, inhibits activation of NLRP3 inflammasome in schwann cells after sciatic nerve injury.

Liu G, Li W, Jiang S, Liang J, Song M, Wang L, Wang X, Liu X, Yang Z, Zhang L, Yang Y, Zhang B

European journal of pharmacology9 Apr 2025Cited by 3 (Europe PMC)

PMID40216181 (opens in a new tab)DOI10.1016/j.ejphar.2025.177610 (opens in a new tab)PepBankPUB-40216181
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with sciatic nerve crush injury, ARA290 inhibited the early inflammatory response.

    In plain wordsIn rats with a crushed sciatic nerve, ARA290 reduced early inflammation.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    DecreaseEarly inflammatory response
    Study

    ratn: not reported in source

    sciatic nerve crush injury model
    Outcome group
    Inflammation markers · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In our study, we demonstrated that both EPO and pyroglutamic acid helix B surface peptide (pHBSP, also known as ARA290) inhibit the early inflammatory response and promote functional recovery after sciatic nerve crush injury in rat models.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats with sciatic nerve crush injury, ARA290 promoted functional recovery.

    In plain wordsIn rats with a crushed sciatic nerve, ARA290 helped functional recovery.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    IncreaseFunctional recovery
    Study

    ratn: not reported in source

    sciatic nerve crush injury model
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In our study, we demonstrated that both EPO and pyroglutamic acid helix B surface peptide (pHBSP, also known as ARA290) inhibit the early inflammatory response and promote functional recovery after sciatic nerve crush injury in rat models.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In rats with sciatic nerve injury, ARA290 treatment inhibited activation of the NLRP3 inflammasome in Schwann cells.

    In plain wordsIn rats with nerve injury, ARA290 reduced activation of an inflammation complex (NLRP3) in Schwann cells.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    DecreaseNLRP3 inflammasome activation in Schwann cells
    Study

    ratn: not reported in source

    sciatic nerve crush injury model
    Outcome group
    Inflammation markers · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    the activation of NLRP3 inflammasome in Schwann cells is inhibited after EPO and ARA290 treatment.
    1 context sentence
    Summary · context
    In our study, we demonstrated that both EPO and pyroglutamic acid helix B surface peptide (pHBSP, also known as ARA290) inhibit the early inflammatory response and promote functional recovery after sciatic nerve crush injury in rat models.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In rats with sciatic nerve injury, ARA290 inhibited NF-κB phosphorylation in Schwann cells.

    In plain wordsIn rats with nerve injury, ARA290 reduced activation of the inflammation signal NF-κB in Schwann cells.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    DecreaseNF-κB phosphorylation
    Study

    ratn: not reported in source

    sciatic nerve crush injury model
    Outcome group
    Inflammation markers · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Our study further demonstrated that EPO and ARA290 inhibit the activation of NLRP3 inflammasome in Schwann cells by inhibiting NF-κB phosphorylation and reducing reactive oxygen species (ROS) production.
    1 context sentence
    Summary · context
    In our study, we demonstrated that both EPO and pyroglutamic acid helix B surface peptide (pHBSP, also known as ARA290) inhibit the early inflammatory response and promote functional recovery after sciatic nerve crush injury in rat models.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In rats with sciatic nerve injury, ARA290 reduced reactive oxygen species production in Schwann cells.

    In plain wordsIn rats with nerve injury, ARA290 reduced production of reactive oxygen species in Schwann cells.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    DecreaseReactive oxygen species production
    Study

    ratn: not reported in source

    sciatic nerve crush injury model
    Outcome group
    Inflammation markers · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Our study further demonstrated that EPO and ARA290 inhibit the activation of NLRP3 inflammasome in Schwann cells by inhibiting NF-κB phosphorylation and reducing reactive oxygen species (ROS) production.
    1 context sentence
    Summary · context
    In our study, we demonstrated that both EPO and pyroglutamic acid helix B surface peptide (pHBSP, also known as ARA290) inhibit the early inflammatory response and promote functional recovery after sciatic nerve crush injury in rat models.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.